In colorectal cancer, hepatocellular carcinoma and prostate cancer, DANCR functions as an oncogene; on the contrary, another report indicated that DANCR functions as a tumour suppressor in breast cancer via degrading the epigenetic tumour regulator EZH2 13, 14, 15, 16. This evidence concerns the gene EZH2 and Familial prostate cancer.